FDA prioritizes post-marketing drug safety, report says

The FDA says it's spending as much time and money on tracking post-market drug safety as it does on scrutinizing candidates before approval. The agency has required 385 post-marketing studies since 2008 and asked for safety-related label changes 65 times, an FDA report says. Report | Release